Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Go back to Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia| Celgene Corp. (NASDAQ: CELG) | Delayed: 108.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $108.24 | 52 Week High | $127.00 | |||
| Open | $7.85 | 52 Week Low | $93.05 | |||
| Day High | $108.24 | P/E | 32.12 | |||
| Day Low | $108.24 | EPS | $3.37 | |||
| Volume | 0 | |||||
| ACCELERON PHARMA (NASDAQ: XLRN) | Delayed: 178.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $178.75 | 52 Week High | $50.86 | |||
| Open | $178.75 | 52 Week Low | $22.67 | |||
| Day High | $178.75 | P/E | 16.93 | |||
| Day Low | $178.75 | EPS | $10.56 | |||
| Volume | 158,297 | |||||
